According to a recent announcement, Thermo Fisher Scientific, a global leader in serving science, has opened its media manufacturing site in Scotland.
The company manufactures important products that are used for vaccines and biotherapeutics to prevent and treat illnesses such as dengue fever and influenza. Now these products will be produced in a new, state-of-the-art facility located near Glasgow.
The main purpose of the facility will be to develop innovative, proprietary dry media powder called Gibco Advanced Granulation Technology (AGT) to create biologics like anti-cancer therapeutics, vaccines and similar life-saving drugs and treatments.
“This is a strategically important facility that will secure supplies for our target markets all over the world,” Mark Smedley, president of Europe, Middle East and Africa, Life Sciences Solutions, for Thermo Fisher, said. “It’s important to choose the right location for a factory of this significance, and we felt the depth of experience, skills and expertise at Inchinnan made it the perfect place to make this investment.”
These products are
single-component and free of particulates and animal origins. AGT
decreases the necessary parts for cell culture manufacturing processes
and provides customers with the same efficiency of traditional liquid
media minus the transportation, cost, and storage problems.
"Congratulations to Thermo Fisher on the opening of their impressive new facility at Inchinnan,” Scottish Development International and Scottish Enterprise International Operations Managing Director Paul Lewis said. "Scotland is already home to a thriving life sciences cluster, which is recognised worldwide as one of the most accessible, well-connected and collaborative in Europe. It is major investments like this that allow us to continue to attract ambitious, international companies such as Thermo Fisher to not only locate in Scotland but to strengthen their business base here and to invest in long-term growth."